Context Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.8%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.45next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results Release | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
CTIM-76 Phase 1a Overall Response Rate (ORR) in Platinum-Resistant Ovarian Cancer (PROC) Quarterly29.0%Target: Maintain or improve ORR in Phase 100b expansion cohorts%
CTIM-76 Phase 1a Disease Control Rate (DCR) in PROC Quarterly57.0%Target: Sustain high disease control rate with durable responses exceeding 6 months
Cash and Cash Equivalents Quarterly54.5MTarget: Sufficient to fund operations into mid-2027
Quarterly Research and Development (R&D) Expenses Quarterly7MTarget: Manageable spend aligned with clinical trial progression
Watch Items
- CT-95 Phase 1a Interim Clinical DataTrigger: September 2026 data releaseAction: Evaluate safety, tolerability, and preliminary efficacy (ORR/DCR) in mesothelin-expressing solid tumors to determine dose expansion strategy.
- CT-202 Phase 1 First-in-Human Trial InitiationTrigger: First patient dosed in Q3 2026Action: Monitor clinical site activation and patient enrollment in Australia following HREC approval and TGA CTN acknowledgement.
- CTIM-76 Dosing Regimen TransitionTrigger: Initiation of every-three-week (Q3W) dosing in 2H 2026Action: Analyze pharmacokinetic and safety profiles of the Q3W regimen to optimize dosing for the planned 2027 Phase 1b expansion.
- BioAtla License Amendment PaymentsTrigger: Final payment of $2.0 million due by August 1, 2026Action: Ensure timely cash transfer to complete the buyout of all future milestone and royalty obligations for CT-202.
Research as of 19 Jun 2026